Web design for companies that answer to a regulator.
We are a pharmaceutical web design agency working with laboratories, biotech and medtech companies across Europe. We design corporate pharmaceutical websites, product ranges and HCP areas around the way medical, regulatory and marketing teams actually review and approve content.
Design work for regulated companies is less about visual trends and more about structure: who sees what, which product can be shown in which market, and how a page survives medical and regulatory review.
A pharmaceutical web design agency understands the approval, access and market constraints that shape pharmaceutical websites. The site has to separate public, professional and restricted content, product presentation changes by market, and every page passes a review the agency does not control.
Corporate and product websites, HCP and patient areas, distributor sites, design systems, multilingual rollouts, UX/UI, redesigns and the front-end implementation that goes with them. Design and build in the same engagement.
Market access, regulatory medical writing, pharmacovigilance services and medical affairs. Those services require specialist teams outside our scope.
Every figure here comes from a pharmaceutical web design project that shipped. As a pharmaceutical web design agency we design corporate sites, product ranges and professional areas for laboratories, biotech and medtech companies.
The same brief — "we need a new website" — means something different for a laboratory with a regulated portfolio than for a vaccine manufacturer or an allergy specialist.
The ones that come up in almost every first design conversation.
Three things. Content passes a review process the agency does not control, so structure has to survive edits. The same product may be shown differently, or not at all, depending on the market. And the site usually serves two audiences with opposite needs — patients and healthcare professionals — which has to be resolved in the architecture rather than with a disclaimer.
Yes, and usually we do. Most pharmaceutical groups already have a global identity and the local team has limited freedom. Our job in that case is to build the digital system on top of it — components, hierarchies and states that the guidelines never covered because they were written for print.
We design around the workflow rather than fighting it. That means content blocks that can be swapped without breaking layout, clear separation between approved and editable areas, and a structure where a rejected claim does not force a redesign of the page it sits on.
We do both, and treat them as one engagement rather than a handoff. Splitting design from development is where structural decisions disappear — responsive behaviour, component states, multilingual layout — because the team building the site did not make them. Our process keeps the same people from wireframe through launch, which shortens review cycles and avoids rebuilding decisions twice.
Typically three to six months from kick-off to go-live. The variable is rarely design or development — it is how long internal review takes on your side, and how much product data has to be restructured before it can be published.
Yes, and that is usually one of the main reasons companies come to us. We build a component-based backend so your marketing team can create and update pages without a developer, working within the structure and design system that was already approved. Anything outside that structure, such as a new layout type or a new field, is a small development request rather than a rebuild.
A corporate site, an HCP area, a redesign or a multilingual rollout. Tell us the context and the scope you have in mind and we will tell you how we would approach the pharmaceutical web design work.